Ibritumomab tiuxetan (90Y) is a monoclonal antibody that is used in the treatment of certain types of non-Hodgkin's lymphoma. It is a radiotherapeutic agent that is designed to deliver radiation directly to cancer cells. The antibody is linked to a radioactive isotope, yttrium-90, which has a short half-life and is released in the body once it binds to the cancer cells. The radiation produced by the decay of the yttrium-90 atom then kills the cancer cells. Ibritumomab tiuxetan is typically administered through intravenous injection, and the dose and duration of therapy are based on the patient's individual situation.
Ibritumomab tiuxetan (90Y), also known by the brand name Zevalin, is a radiopharmaceutical drug used to treat a specific type of cancer. Here's a breakdown of its key features:
Type of Cancer:
- Targets B-cell non-Hodgkin's lymphoma (NHL): This is a type of cancer that originates from B-lymphocytes, a kind of white blood cell. It's categorized as non-Hodgkin's lymphoma, which is different from Hodgkin's lymphoma.
How it Works:
- Antibody-Radioisotope Conjugate: Ibritumomab tiuxetan combines two components:
- Ibritumomab: This is a monoclonal antibody, a lab-made protein that recognizes and attaches to a specific antigen (marker) on the surface of B-cells. In this case, the target antigen is CD20, which is present on both healthy and cancerous B-cells.
- Yttrium-90 (90Y): This is a radioactive isotope that emits beta particles. These particles damage cells they come into close contact with, including cancerous B-cells.
- Targeted Therapy: By attaching to the CD20 antigen, the ibritumomab component delivers the radioactive yttrium-90 directly to cancer cells. This targeted approach aims to minimize radiation exposure to healthy tissues.
Applications:
- Relapsed or Refractory B-cell NHL: Ibritumomab tiuxetan is used to treat certain types of B-cell NHL that have either come back after initial treatment (relapsed) or haven't responded well to previous therapies (refractory).
- Follicular Lymphoma: In some cases, it can also be used as a first-line treatment for a specific subtype of B-cell NHL called follicular lymphoma, particularly in patients who achieve a partial or complete response to initial chemotherapy.
Administration:
- Ibritumomab tiuxetan is typically given as a single intravenous (IV) infusion.
Important Considerations:
- Side Effects: Like many medications, Ibritumomab tiuxetan can cause side effects, including low blood cell counts, fatigue, nausea, and increased risk of infection.
- Not for Everyone: This medication is not suitable for everyone and has specific criteria for use.
- Doctor's Supervision: It's crucial to consult with a doctor to determine if Ibritumomab tiuxetan is the right treatment option and to be monitored for potential side effects.
Additional Notes:
- Ibritumomab tiuxetan is a complex medication, and this description provides a simplified overview.
- If you have any further questions or need more specific details, talking to your doctor or a healthcare professional is essential.